Nanopublications LDF server

Matches in Nanopublications for { ?s ?p "[We tested a panel of markers composed of the anti-apoptotic protein FLIP and its transcriptional regulators Sp1 and Sp3 using prostate tissues from 64 patients with recurrent and non-recurrent cancer who underwent radical prostatectomy as primary treatment for prostate cancer and were followed with PSA measurements for at least 5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine."@en ?g. }

• assertion description "[We tested a panel of markers composed of the anti-apoptotic protein FLIP and its transcriptional regulators Sp1 and Sp3 using prostate tissues from 64 patients with recurrent and non-recurrent cancer who underwent radical prostatectomy as primary treatment for prostate cancer and were followed with PSA measurements for at least 5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We tested a panel of markers composed of the anti-apoptotic protein FLIP and its transcriptional regulators Sp1 and Sp3 using prostate tissues from 64 patients with recurrent and non-recurrent cancer who underwent radical prostatectomy as primary treatment for prostate cancer and were followed with PSA measurements for at least 5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We tested a panel of markers composed of the anti-apoptotic protein FLIP and its transcriptional regulators Sp1 and Sp3 using prostate tissues from 64 patients with recurrent and non-recurrent cancer who underwent radical prostatectomy as primary treatment for prostate cancer and were followed with PSA measurements for at least 5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We tested a panel of markers composed of the anti-apoptotic protein FLIP and its transcriptional regulators Sp1 and Sp3 using prostate tissues from 64 patients with recurrent and non-recurrent cancer who underwent radical prostatectomy as primary treatment for prostate cancer and were followed with PSA measurements for at least 5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We tested a panel of markers composed of the anti-apoptotic protein FLIP and its transcriptional regulators Sp1 and Sp3 using prostate tissues from 64 patients with recurrent and non-recurrent cancer who underwent radical prostatectomy as primary treatment for prostate cancer and were followed with PSA measurements for at least 5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• assertion description "[We tested a panel of markers composed of the anti-apoptotic protein FLIP and its transcriptional regulators Sp1 and Sp3 using prostate tissues from 64 patients with recurrent and non-recurrent cancer who underwent radical prostatectomy as primary treatment for prostate cancer and were followed with PSA measurements for at least 5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." provenance.
• NP1017183.RAhfOiHIhr7iybUghPaKhaa46pjcRDMoRjmNOwFkZsIVY130_assertion description "[We tested a panel of markers composed of the anti-apoptotic protein FLIP and its transcriptional regulators Sp1 and Sp3 using prostate tissues from 64 patients with recurrent and non-recurrent cancer who underwent radical prostatectomy as primary treatment for prostate cancer and were followed with PSA measurements for at least 5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1017183.RAhfOiHIhr7iybUghPaKhaa46pjcRDMoRjmNOwFkZsIVY130_provenance.
• NP1017186.RAnhrZyskGK06GM6aM0c9H2iZ3u3USD6bLzuUHuLEhQQw130_assertion description "[We tested a panel of markers composed of the anti-apoptotic protein FLIP and its transcriptional regulators Sp1 and Sp3 using prostate tissues from 64 patients with recurrent and non-recurrent cancer who underwent radical prostatectomy as primary treatment for prostate cancer and were followed with PSA measurements for at least 5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1017186.RAnhrZyskGK06GM6aM0c9H2iZ3u3USD6bLzuUHuLEhQQw130_provenance.
• NP247879.RA8t2t8xR4N2j2n-b-CYL9DldHR0k9SAyG2B4Q5zKPrhQ130_assertion description "[We tested a panel of markers composed of the anti-apoptotic protein FLIP and its transcriptional regulators Sp1 and Sp3 using prostate tissues from 64 patients with recurrent and non-recurrent cancer who underwent radical prostatectomy as primary treatment for prostate cancer and were followed with PSA measurements for at least 5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP247879.RA8t2t8xR4N2j2n-b-CYL9DldHR0k9SAyG2B4Q5zKPrhQ130_provenance.
• NP807336.RAM-4esfzwY4wNeZtFoiGZJjwVnAQiWVsOGDt_spL1FUo130_assertion description "[We tested a panel of markers composed of the anti-apoptotic protein FLIP and its transcriptional regulators Sp1 and Sp3 using prostate tissues from 64 patients with recurrent and non-recurrent cancer who underwent radical prostatectomy as primary treatment for prostate cancer and were followed with PSA measurements for at least 5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP807336.RAM-4esfzwY4wNeZtFoiGZJjwVnAQiWVsOGDt_spL1FUo130_provenance.
• NP1017182.RAFrddY3oZRpQq89_X4RIT4Rz4Ppyflp0m_avNKUn-uLU130_assertion description "[We tested a panel of markers composed of the anti-apoptotic protein FLIP and its transcriptional regulators Sp1 and Sp3 using prostate tissues from 64 patients with recurrent and non-recurrent cancer who underwent radical prostatectomy as primary treatment for prostate cancer and were followed with PSA measurements for at least 5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1017182.RAFrddY3oZRpQq89_X4RIT4Rz4Ppyflp0m_avNKUn-uLU130_provenance.
• NP1017184.RAGnB3zQ072qBgyr-o69Hvdq5Mooc04mAztxhpt3T-yD4130_assertion description "[We tested a panel of markers composed of the anti-apoptotic protein FLIP and its transcriptional regulators Sp1 and Sp3 using prostate tissues from 64 patients with recurrent and non-recurrent cancer who underwent radical prostatectomy as primary treatment for prostate cancer and were followed with PSA measurements for at least 5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1017184.RAGnB3zQ072qBgyr-o69Hvdq5Mooc04mAztxhpt3T-yD4130_provenance.
• NP1017187.RAIRj47aZthVJ_VoJGpBBkYvqwPkBreXEhZsvCS3lX4X4130_assertion description "[We tested a panel of markers composed of the anti-apoptotic protein FLIP and its transcriptional regulators Sp1 and Sp3 using prostate tissues from 64 patients with recurrent and non-recurrent cancer who underwent radical prostatectomy as primary treatment for prostate cancer and were followed with PSA measurements for at least 5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1017187.RAIRj47aZthVJ_VoJGpBBkYvqwPkBreXEhZsvCS3lX4X4130_provenance.
• NP807322.RA-_6YXIjMEARvRoCvouODaVoLqcw5EH0vqYMLXIbciXM130_assertion description "[We tested a panel of markers composed of the anti-apoptotic protein FLIP and its transcriptional regulators Sp1 and Sp3 using prostate tissues from 64 patients with recurrent and non-recurrent cancer who underwent radical prostatectomy as primary treatment for prostate cancer and were followed with PSA measurements for at least 5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP807322.RA-_6YXIjMEARvRoCvouODaVoLqcw5EH0vqYMLXIbciXM130_provenance.
• NP807323.RAzBLC2lo5JQGJZ_VXiiwti2zTGHtbalrmGBB94LYt9Jc130_assertion description "[We tested a panel of markers composed of the anti-apoptotic protein FLIP and its transcriptional regulators Sp1 and Sp3 using prostate tissues from 64 patients with recurrent and non-recurrent cancer who underwent radical prostatectomy as primary treatment for prostate cancer and were followed with PSA measurements for at least 5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP807323.RAzBLC2lo5JQGJZ_VXiiwti2zTGHtbalrmGBB94LYt9Jc130_provenance.
• NP1017185.RA5c6GhsKCeMZ0p_JN0CAhUHQ6ufh2mFaesVq2cLwsRDA130_assertion description "[We tested a panel of markers composed of the anti-apoptotic protein FLIP and its transcriptional regulators Sp1 and Sp3 using prostate tissues from 64 patients with recurrent and non-recurrent cancer who underwent radical prostatectomy as primary treatment for prostate cancer and were followed with PSA measurements for at least 5 years.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1017185.RA5c6GhsKCeMZ0p_JN0CAhUHQ6ufh2mFaesVq2cLwsRDA130_provenance.